Breaking News: A 28-year-old woman from Co Kilkenny has gone to the High Court in a case that raises urgent questions about access to rare disease treatment in Ireland. Emily Felix, who lives with Friedreich’s ataxia, is seeking orders aimed at forcing a decision on HSE approval and funding for a medicine that may slow the progression of her condition.
The case is one of the most closely watched health and legal stories in Ireland News today because it sits at the intersection of patient rights, public drug reimbursement and the pace of decision-making within the Irish health system. It also highlights the real-world impact that delays can have for people with progressive illnesses where lost time cannot be recovered.
Breaking News Ireland: What happened in the High Court?
Emily Felix has brought judicial review proceedings against the HSE and the Minister for Health over the status of an application concerning omaveloxolone, a drug marketed as Skyclarys. The medicine is designed to slow the progression of Friedreich’s ataxia, a rare inherited neuromuscular disease.
On Tuesday, Judge Cian Ferriter granted permission for the case to proceed. That means the court accepted there are arguable grounds for the legal challenge to move forward. The matter is due to return before the court again in September.
According to the case outlined in court, Felix wants the High Court to direct the HSE to finalise its decision on the drug’s approval, reimbursement and funding. She is also seeking an interim arrangement that would allow access to the treatment while the HSE process remains unresolved.
This Latest News Ireland case does not decide whether the medicine will be funded. Instead, it focuses on whether the decision-making process has been unlawfully delayed and what relief, if any, the court should grant.
Who is Emily Felix and why does the case matter?
Felix, from Co Kilkenny, was diagnosed with Friedreich’s ataxia at the age of 12. She is now 28 and, according to materials before the court, relies fully on a wheelchair and needs help with virtually all aspects of daily life.
She works for the Central Bank of Ireland and is also studying to become a solicitor. Her case has drawn attention not only because of the seriousness of her illness, but because it illustrates how patients with rare conditions can become caught in lengthy reimbursement processes.
Her legal team says she has experienced substantial deterioration in recent years, including worsening speech, mobility, fatigue and swallowing difficulties. In a progressive condition such as Friedreich’s ataxia, that deterioration cannot be reversed.
That is why this Irish News story has significance beyond a single patient. It speaks to a broader issue in HSE News and Health News Ireland: how the State assesses high-cost medicines for small patient groups, and whether those systems can respond quickly enough when a disease continues to advance.
What is Friedreich’s ataxia and what does Skyclarys do?
Friedreich’s ataxia is a rare, inherited and progressive neurological condition. It affects the nervous system and can damage coordination, balance, movement, speech and other physical functions over time. Because it is progressive, symptoms typically worsen rather than improve.
Skyclarys, the trade name for omaveloxolone, is not a cure. Its significance lies in its potential to slow disease progression. For patients with degenerative illnesses, slowing decline can be medically and practically important, especially where day-to-day independence is already affected.
Key facts in this News Today case include:
- The drug is licensed by the European Medicines Agency for patients aged 16 and over.
- European Commission market authorisation was granted in February 2024.
- The medicine is available in a number of EU member states.
- A pricing and reimbursement application was made to the HSE in August 2024.
For readers following Ireland Headlines on access to medicines, those dates are central. The legal complaint is rooted in the gap between European approval and a final Irish reimbursement outcome.
How the HSE reimbursement process became the focus
Under Ireland’s public medicines system, pharmaceutical companies can apply to have a new drug reimbursed through the HSE. If approved, eligible public patients may gain access through State-funded schemes.
In this case, Biogen submitted its pricing and reimbursement application for Skyclarys in August 2024. In December 2025, the National Centre for Pharmacoeconomics recommended that omaveloxolone should not be considered for reimbursement on cost-effectiveness grounds.
That recommendation did not end the process. Biogen then engaged further with the HSE’s Corporate Pharmaceutical Unit and submitted a commercial proposal in May 2026. The application, according to the material before the court, remains under consideration.
This is where the case enters the territory of Irish Courts and Breaking News Ireland. Felix argues that further delay has real and irreversible consequences because every month without treatment may reduce the practical benefit of receiving the drug later.
Why timing matters in progressive illness
For many medicines, delay is frustrating. For progressive neurological disease, delay can be life-altering. If a treatment is intended to slow decline rather than reverse damage already done, late access may mean patients miss the period when benefit could be greatest.
That is a key reason this case matters in Ireland Today and why it may be followed closely by patient advocates, clinicians and policymakers involved in rare disease care.
Official information and what the court has confirmed
The court has confirmed that permission has been granted for the judicial review to proceed. That is a procedural stage, not a ruling on the merits of the claim.
What is confirmed from the proceedings so far:
- Felix is seeking orders related to the HSE decision-making process.
- She wants a final determination on approval, reimbursement, funding and access.
- She is also seeking an interim access arrangement while the process continues.
- The case is expected to be mentioned again in September.
As with many developing legal stories in Latest News, the court will ultimately decide whether the HSE acted unlawfully or whether the relief sought should be granted. Until then, the underlying reimbursement process remains live.
What happens next?
The next immediate step is the return of the case before the High Court. The HSE and the Minister for Health will have an opportunity to respond in the proceedings, and the court will then consider the legal arguments in more detail.
There are several possible outcomes:
- The court could require a faster determination by the HSE.
- The court could decline to grant the relief sought.
- An interim arrangement could be considered while the case is ongoing.
- The reimbursement process could move on separately through engagement between the parties.
For people following Irish Government, Public Services Ireland and Consumer News Ireland, the wider question is whether this case prompts fresh scrutiny of how Ireland handles access to high-cost treatments for rare conditions.
More Ireland live updates, legal developments and health policy coverage on NewsDigest
Frequently asked questions
What is the case about?
It concerns a High Court challenge by Emily Felix, who says there has been an unlawful delay in the HSE decision on funding and access to Skyclarys for Friedreich’s ataxia.
Has the court ordered the HSE to fund the drug?
No. The court has so far granted permission for the judicial review to proceed. It has not yet ruled on whether the medicine must be funded.
Is Skyclarys approved in Europe?
Yes. The drug has European regulatory approval for eligible patients aged 16 and over, but national reimbursement decisions are handled separately by each country.
Why is this story important?
It highlights how delays in access to treatment can have serious consequences for people with progressive illnesses, especially where medicines are designed to slow deterioration rather than reverse it.
Conclusion
This Breaking News case from Kilkenny is about far more than legal procedure. It goes to the heart of how quickly the Irish health system can respond when a patient with a rare, worsening condition is waiting for a drug that may preserve function for longer. As the High Court case moves forward, it is likely to remain one of the most important Irish Headlines in health, law and public policy.
For readers tracking Latest Irish News, the central takeaway is clear: when treatment windows are narrow and disease progression is irreversible, delays are not just administrative. They can shape a patient’s future in lasting ways.
